Needham & Company LLC Reiterates “Buy” Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $10.00 target price on the stock. Needham & Company LLC’s target price points to a potential upside of 352.49% from the stock’s previous close.

Several other equities research analysts have also recently commented on the stock. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Down 3.9 %

AUTL stock opened at $2.21 on Monday. Autolus Therapeutics has a twelve month low of $2.07 and a twelve month high of $7.37. The business’s 50-day simple moving average is $2.81 and its 200 day simple moving average is $3.59. The company has a market cap of $588.07 million, a PE ratio of -1.83 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company earned ($0.26) EPS. On average, equities research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. ProShare Advisors LLC bought a new position in Autolus Therapeutics during the 2nd quarter worth $43,000. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics during the 3rd quarter worth $51,000. Daiwa Securities Group Inc. grew its stake in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after buying an additional 15,293 shares during the period. Herbst Group LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at approximately $91,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Autolus Therapeutics by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.